The Best New Medications & Treatments for Psoriasis

Why Psoriasis Treatment Has Changed So Much

Psoriasis is a chronic immune-mediated disease in which inflammatory signaling causes skin cells to multiply too quickly. That accelerated production creates raised, scaly plaques that may itch, crack, burn, or bleed. Psoriasis can also affect the nails and joints, and its severity cannot always be judged by body-surface area alone. A small plaque on the genitals, palms, soles, or scalp may cause more disruption than larger plaques hidden beneath clothing.

Modern medications target specific inflammatory pathways, including interleukin-23, interleukin-17, TYK2, PDE4, and the interleukin-36 receptor. This precision can improve effectiveness while avoiding some of the widespread immune suppression associated with older systemic drugs. Dermatologists still use proven treatments such as topical corticosteroids, methotrexate, cyclosporine, acitretin, and narrowband UVB phototherapy, but the menu is now much larger.

1. Icotyde: A New Oral IL-23 Treatment

Why icotrokinra is a major development

Icotyde, the brand name for icotrokinra, received its initial U.S. approval in March 2026. It is a targeted oral peptide that blocks the interleukin-23 receptor, a pathway that plays a central role in plaque psoriasis inflammation. It is approved for moderate-to-severe plaque psoriasis in adults and patients 12 years or older who weigh at least 88 pounds and are candidates for systemic treatment or phototherapy.

The recommended dose is one 200-milligram tablet daily. It must be taken with water on an empty stomach upon waking, followed by a wait of at least 30 minutes before eating. That is slightly fussier than swallowing a pill with breakfast, but still simpler than giving yourself an injection while negotiating with a nervous bathroom mirror.

In one pivotal trial, 65% of participants taking icotrokinra were rated clear or almost clear at week 16, compared with 8% receiving placebo. Among adolescents evaluated in that trial, 70% achieved at least a 90% improvement in the Psoriasis Area and Severity Index, or PASI 90. These figures come from controlled trials and cannot predict an individual patient’s response.

Who may find it appealing

Icotyde may be attractive to people who need systemic treatment but strongly prefer a pill over injections. Its precise IL-23 receptor targeting also distinguishes it from older oral immune-modulating drugs. Before treatment, clinicians may evaluate infection risks, tuberculosis history, vaccinations, kidney function, and other medical conditions.

Common adverse reactions reported in the prescribing information include headache, nausea, cough, fungal infection, and fatigue. Because the medication affects immune signaling, patients should promptly report fever, persistent cough, unusual skin sores, or other signs of infection.

2. Bimzelx: Dual IL-17A and IL-17F Blockade

Bimzelx, or bimekizumab-bkzx, is an injectable biologic approved in the United States for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Unlike medications that inhibit only IL-17A, Bimzelx inhibits both IL-17A and IL-17F, two closely related inflammatory cytokines.

Its biggest selling point is not subtle: very high levels of skin clearance. In a long-term extension study, 76.2% of continuously treated participants had complete PASI clearance at approximately one year, while 64.7% maintained complete clearance at approximately four years. Extension studies include selected participants who remain in follow-up, so these results should not be interpreted as a guarantee for everyone.

Important safety considerations

Blocking the IL-17 pathway can increase susceptibility to infections, particularly oral candidiasis, commonly called thrush. Screening and monitoring may include tuberculosis testing, liver enzymes, vaccination status, and symptoms of inflammatory bowel disease. Anyone with Crohn’s disease, ulcerative colitis, recurring yeast infections, or significant liver problems should discuss those issues before treatment.

Bimzelx may be a strong option when near-complete clearance is an important goal, but its risks, injection schedule, insurance coverage, and the patient’s medical history all belong in the decision.

3. Sotyktu: A Selective TYK2 Inhibitor in a Daily Pill

Sotyktu, or deucravacitinib, was the first selective TYK2 inhibitor approved for adults with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy. It is taken as a six-milligram tablet once daily, with or without food.

TYK2 helps transmit signals from inflammatory cytokines, including IL-23 and IL-12. Deucravacitinib binds to the regulatory portion of the TYK2 enzyme rather than broadly blocking several Janus kinase pathways. Four-year follow-up data have shown durable effectiveness and a generally consistent safety profile among study participants who continued treatment.

What patients should know

Possible adverse effects include upper respiratory infections, mouth ulcers, acne, folliculitis, cold sores, and changes in certain laboratory values. Tuberculosis screening and evaluation for infections are generally performed before treatment. The FDA label also notes that it is not known whether selective TYK2 inhibition carries all the risks associated with broader JAK inhibition.

Sotyktu remains useful for adults who prefer oral treatment and want an option that usually requires less routine laboratory monitoring than some older systemic medications. It is not recommended in combination with other powerful immunosuppressants.

4. Zoryve Cream and Foam: Steroid-Free Treatment for Difficult Areas

Zoryve contains roflumilast, a phosphodiesterase-4 inhibitor that reduces inflammatory activity inside skin cells. The medication is available in different topical formulations, which matters because psoriasis has a talent for appearing in places where ordinary creams are inconvenient.

Zoryve cream

Zoryve cream 0.3% is applied once daily and is approved for plaque psoriasis, including intertriginous psoriasis in skin folds. In June 2026, its U.S. indication was expanded to include children as young as age two. This gives families a nonsteroidal prescription option for areas such as the face, groin, armpits, and other sensitive locations where prolonged use of potent corticosteroids may be undesirable.

Zoryve foam

Zoryve foam 0.3% is approved for plaque psoriasis of the scalp and body in adults and adolescents 12 years or older. Foam can spread through hair more easily than a thick ointment, making it especially practical for scalp psoriasis. In controlled trials, scalp treatment success at week eight was achieved by 66.4% of participants in one pivotal study, compared with 27.8% using vehicle foam. Improvements in body plaques and itching were also reported.

Possible adverse effects include headache, diarrhea, nausea, insomnia, and upper respiratory symptoms. Roflumilast topicals are contraindicated in people with moderate-to-severe liver impairment. The foam’s propellant is flammable, so it should not be used near flames, smoking materials, or intense heat.

5. Vtama: A Once-Daily Aryl Hydrocarbon Receptor Cream

Vtama, or tapinarof cream 1%, is a nonsteroidal topical treatment approved for plaque psoriasis in adults. It activates the aryl hydrocarbon receptor, which influences inflammation, antioxidant responses, and skin-barrier function.

Patients apply a thin layer once daily. Unlike potent topical steroids, tapinarof does not have the same concerns about steroid-related skin thinning. In two phase 3 studies, approximately 35% to 40% of treated participants reached the main physician-rated success endpoint after 12 weeks, compared with about 6% using vehicle cream. Some patients who became clear maintained improvement for a period after stopping treatment in the extension study.

The most frequently reported problems include folliculitis, contact dermatitis, itching, headache, and cold-like symptoms. Folliculitis can resemble small acne bumps around hair follicles. It is usually manageable, but nobody enjoys discovering that their psoriasis cream has invited a tiny committee of pimples to the meeting.

6. Spevigo: A Breakthrough for Generalized Pustular Psoriasis

Generalized pustular psoriasis, or GPP, is a rare and potentially life-threatening form of psoriasis characterized by widespread sterile pustules, fever, weakness, and systemic inflammation. It is not simply an unusually angry version of plaque psoriasis and may require urgent hospital treatment.

Spevigo, or spesolimab-sbzo, blocks the interleukin-36 receptor. It is approved for adults and adolescents 12 years or older who weigh at least 88 pounds. Intravenous Spevigo can be used to treat an active GPP flare, while subcutaneous maintenance dosing can reduce the likelihood of future flares.

In a prevention study, GPP flares occurred in 10% of participants receiving subcutaneous spesolimab compared with 52% receiving placebo through the study period. Infection screening, tuberculosis evaluation, vaccination review, and monitoring for infusion or allergic reactions are important parts of treatment.

7. Otezla XR and More Convenient Oral Treatment

Apremilast is not a new molecule, but Otezla XR introduced a useful convenience upgrade. The extended-release tablet allows eligible patients to take 75 milligrams once daily instead of immediate-release Otezla twice daily. It is approved for adults with plaque psoriasis who qualify for systemic therapy or phototherapy, as well as eligible pediatric patients six years or older who meet weight requirements.

Apremilast inhibits PDE4 and generally does not require the tuberculosis screening used for many biologics. However, nausea, diarrhea, vomiting, headache, weight loss, depression, medication interactions, and kidney function must be considered. Once-daily dosing does not make these concerns disappear, but it may make adherence easier for people whose morning routine already resembles air-traffic control.

Are Older Biologics Still Among the Best Treatments?

Absolutely. New does not automatically mean better for every patient. Established IL-23 inhibitors such as guselkumab, risankizumab, and tildrakizumab can provide durable clearance with relatively infrequent maintenance injections. IL-17 inhibitors such as secukinumab and ixekizumab often act quickly and can be particularly useful when rapid skin improvement is needed. Ustekinumab, TNF inhibitors, and their biosimilars remain important options for selected patients.

Biosimilars are highly similar to already approved biologic medications and may improve treatment access when insurance plans prefer them. The practical winner is sometimes not the newest drug but the one a patient can obtain consistently without participating in a monthly prior-authorization treasure hunt.

Biologic selection should also consider psoriatic arthritis, inflammatory bowel disease, recurrent infections, pregnancy plans, cardiovascular health, body weight, previous treatment failures, and how frequently the patient is comfortable injecting medication.

How Doctors Choose the Best Psoriasis Medication

A dermatologist may begin by evaluating the type of psoriasis, percentage of affected skin, plaque thickness, itch, pain, nail disease, joint symptoms, and involvement of high-impact areas. A treatment that appears successful on a body-surface chart may still be inadequate if the patient cannot sleep because of scalp itching or cannot walk comfortably because of cracked soles.

Other decision-making questions include:

• Is the disease limited enough for topical treatment?
• Are the scalp, genitals, hands, feet, nails, or skin folds involved?
• Are swollen joints, morning stiffness, or tendon pain suggesting psoriatic arthritis?
• Does the patient prefer a cream, pill, injection, or office-based light therapy?
• Are there infections, liver disease, kidney disease, inflammatory bowel disease, depression, pregnancy plans, or medication interactions?
• What will insurance cover, and can the treatment be used consistently?

Switching treatments is not failure. Psoriasis can change over time, and a medication that worked beautifully for several years may gradually lose effectiveness. Adjusting the dose, combining a systemic medication with a topical product, or moving to another inflammatory target may restore control.

Experience-Based Scenarios: What New Psoriasis Treatment Can Feel Like

The following are fictional composite scenarios based on common treatment challenges. They are not testimonials from specific patients and should not be used to predict individual results.

The patient who is tired of scalp-treatment gymnastics

Consider a college student with thick scalp plaques who has spent years trying to push greasy ointment through dense hair. The medication may work chemically, but the application process turns bedtime into a low-budget oil-spill documentary. A topical foam can change the experience because it reaches the scalp more easily, dries faster, and is less likely to decorate a pillowcase.

The improvement may not be instantaneous. The first signs of progress could be less itching, fewer visible flakes, and reduced redness before the plaques fully flatten. Consistent application remains essential. A medication cannot perform its finest scientific work while sitting unopened beside the bathroom sink.

The needle-averse adult who needs systemic treatment

Another common scenario involves an adult with plaques covering the trunk, elbows, knees, and scalp who qualifies for a biologic but cannot tolerate the idea of injections. New oral options such as icotrokinra or deucravacitinib may make systemic treatment feel more approachable.

The trade-off is that “just a pill” still requires responsibility. The patient may need infection screening, vaccination review, laboratory testing, and a discussion of other medications. Icotyde also has specific empty-stomach instructions. A phone reminder may become as important as the prescription itself, especially when improvement makes it tempting to forget that the medicine is the reason the skin is calmer.

The patient pursuing nearly clear skin with a biologic

A person with severe plaque psoriasis may start an IL-17 or IL-23 biologic after years of cycling through creams and older pills. Within several months, plaques that once controlled clothing choices and social plans may become faint or disappear. That improvement can feel dramatic, but follow-up remains necessary.

The patient still needs to watch for infections and treatment-specific problems. Someone taking bimekizumab, for example, may develop oral thrush that requires medical attention. A good result is not a reason to ignore side effects; it is a reason to protect the result with appropriate monitoring.

The family seeking a steroid-free option for a young child

Parents of a preschool child with psoriasis in skin folds may worry about repeated corticosteroid use on delicate skin. The expansion of roflumilast cream to children as young as two offers another option to discuss with a pediatric dermatologist.

Real-life success may involve more than plaque clearance. Easier application can reduce arguments at bedtime, less itching may improve sleep, and a treatment suitable for sensitive areas may simplify the family’s routine. Parents still need clear instructions about how much to apply, where to apply it, what side effects to watch for, and when to return for evaluation.

The insurance experience nobody puts in the glossy brochure

Even when a doctor and patient agree on the ideal medication, insurance coverage can reshape the plan. Prior authorization, required trials of older medications, copay rules, specialty pharmacies, and manufacturer assistance programs can delay treatment. Keeping photographs, records of previous therapies, and notes about how psoriasis affects work, sleep, mobility, or mental well-being may help document medical necessity.

The most sustainable treatment is one that combines effectiveness, safety, convenience, and reliable access. A miracle medication that arrives for one month and then disappears into an insurance maze is not a complete treatment strategy.

When to Seek Medical Help Quickly

Contact a healthcare professional promptly if psoriasis suddenly spreads, becomes intensely painful, produces widespread pustules, or is accompanied by fever, chills, dehydration, or weakness. These symptoms may indicate generalized pustular or erythrodermic psoriasis, both of which can require urgent care.

Patients taking systemic medications should also report serious infections, shortness of breath, persistent fever, allergic reactions, new digestive symptoms, unusual mood changes, or other severe adverse effects. Joint swelling, prolonged morning stiffness, heel pain, or sausage-like swelling of a finger or toe should be evaluated for psoriatic arthritis.

Conclusion

The newest psoriasis treatments offer something patients have wanted for decades: meaningful choices. Icotyde brings IL-23 receptor targeting into a once-daily pill. Bimzelx offers exceptionally high skin-clearance potential through dual IL-17A and IL-17F blockade. Sotyktu provides selective TYK2 inhibition in an oral formulation. Zoryve and Vtama expand steroid-free topical care, while Spevigo has transformed treatment for generalized pustular psoriasis.

None of these medications is universally best. The ideal plan depends on psoriasis type, severity, affected locations, joint disease, medical history, safety preferences, lifestyle, and insurance access. A dermatologist can turn that complicated puzzle into a practical treatment strategyand, ideally, one that does not require reorganizing your entire life around a tube of ointment.